Clinical Trial: Predicting Recurrence in HR+/HER2- Early Breast Cancer

U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07484763) titled 'Predicting Recurrence in HR+/HER2- Early Breast Cancer' on March 16.

Brief Summary: Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer constitutes approximately 70% of all breast cancer cases. Although early-stage patients generally have favorable outcomes following standard surgery and adjuvant endocrine therapy, long-term follow-up data reveal a distinct "bimodal" or "long-tail" recurrence pattern, with risks persisting for decades. Recent landmark trials (e.g., NATALEE, MonarchE) have established that combining CDK4/6 inhibitors with endocrine therapy significantly improves inva...